ARVN · Arvinas, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-24 | Smaldone Alsup Laurie |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option award was granted on June 24, 2026. The shares underlying the award shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. |
Stock Option (right to buy)
|
22,714 |
| 2026-06-24 | Kennedy Edward Moore Jr. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock units (each, an "RSU") were granted by the Issuer on June 24, 2026 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. |
Common Stock
|
15,527 |
| 2026-06-24 | Bain Linda |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock units (each, an "RSU") were granted by the Issuer on June 24, 2026 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. |
Common Stock
|
15,527 |
| 2026-06-24 | Kennedy Edward Moore Jr. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option award was granted on June 24, 2026. The shares underlying the award shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. |
Stock Option (right to buy)
|
22,714 |
| 2026-06-24 | Morrison Briggs |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option award was granted on June 24, 2026. The shares underlying the award shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. |
Stock Option (right to buy)
|
22,714 |
| 2026-06-24 | Norwalk Leslie V |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock units (each, an "RSU") were granted by the Issuer on June 24, 2026 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. |
Common Stock
|
15,527 |
| 2026-06-24 | Cunningham Everett |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option award was granted on June 24, 2026. The shares underlying the award shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. |
Stock Option (right to buy)
|
22,714 |
| 2026-06-24 | Morrison Briggs |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock units (each, an "RSU") were granted by the Issuer on June 24, 2026 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. |
Common Stock
|
15,527 |
| 2026-06-24 | Smaldone Alsup Laurie |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock units (each, an "RSU") were granted by the Issuer on June 24, 2026 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. |
Common Stock
|
15,527 |
| 2026-06-24 | Norwalk Leslie V |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option award was granted on June 24, 2026. The shares underlying the award shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. |
Stock Option (right to buy)
|
22,714 |
| 2026-06-24 | Saik Andrew |
Director, Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on June 24, 2024, pursuant to a durable sale instruction. The sale does not represent a discretionary trade. |
Common Stock
|
5,696 |
| 2026-06-24 | Bain Linda |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option award was granted on June 24, 2026. The shares underlying the award shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. |
Stock Option (right to buy)
|
22,714 |
| 2026-06-24 | Cunningham Everett |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock units (each, an "RSU") were granted by the Issuer on June 24, 2026 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. |
Common Stock
|
15,527 |
| 2026-06-17 | Cacace Angela M |
Chief Scientific Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on June 17, 2024 pursuant to a durable sale instruction. The sale does not represent a discretionary trade. |
Common Stock
|
2,576 |
| 2026-05-21 | Teel Randy |
Director, President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on May 21, 2024. The sale does not represent a discretionary trade. |
Common Stock
|
2,209 |
| 2026-05-11 | Berkowitz Noah |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on May 9, 2025. The sale does not represent a discretionary trade. |
Common Stock
|
11,108 |
| 2026-05-11 | Cacace Angela M |
Chief Scientific Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on May 9, 2025. The sale does not represent a discretionary trade. |
Common Stock
|
9,657 |
| 2026-05-11 | Loomis David K |
VP, Chief Accounting Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on May 9, 2025. The sale does not represent a discretionary trade. |
Common Stock
|
1,919 |
| 2026-05-11 | Saik Andrew |
Director, Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on May 9, 2025. The sale does not represent a discretionary trade. |
Common Stock
|
11,139 |
| 2026-05-11 | Teel Randy |
Director, President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on May 9, 2025. The sale does not represent a discretionary trade. |
Common Stock
|
9,657 |
| 2026-03-18 | Berkowitz Noah |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on March 18, 2024. The sale does not represent a discretionary trade. |
Common Stock
|
6,435 |
| 2026-03-06 | Morrison Briggs |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The purchase price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.364 to $13.45, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
Common Stock
|
20,000 |
| 2026-02-27 | Houston John G |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-quarter of the reporting person's restricted stock units (RSUs) granted on February 13, 2025 when the reporting person was serving as President and CEO. The sale does not represent a discretionary trade. |
Common Stock
|
11,787 |
| 2026-02-27 | Houston John G |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-quarter of the reporting person's restricted stock units (RSUs) granted on February 22, 2023 when the reporting person was serving as President and CEO. The sale does not represent a discretionary trade. |
Common Stock
|
4,688 |
| 2026-02-27 | Houston John G |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on February 23, 2024 when the reporting person was serving as President and CEO. The sale does not represent a discretionary trade. |
Common Stock
|
18,822 |
| 2026-02-26 | Teel Randy |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock units (each, an "RSU") were granted by the Issuer on February 26, 2026, pursuant to its 2018 Stock Incentive Plan (the "Plan"), and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: one-quarter of the RSUs will vest on each of February 12, 2027, February 12, 2028, February 12, 2029 and February 12, 2030, subject to the Reporting Person's continued service with the Issuer on each such vesting date. This amendment is being filed to correct an inadvertent clerical error in reporting the number of RSUs awarded on February 26, 2026. The correct number of RSUs awarded was 147,179, not 147,791, as was originally reported on the Form 4 filed on March 2, 2026. Column 5, the amount of securities beneficially owned following reported transaction(s), has also been corrected accordingly. |
Common Stock
|
147,179 |
| 2026-02-26 | Saik Andrew |
Director, Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock units (each, an "RSU") were granted by the Issuer on February 26, 2026, pursuant to its 2018 Stock Incentive Plan (the "Plan"), and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: one-quarter of the RSUs will vest on each of February 26, 2027, February 26, 2028, February 26, 2029 and February 26, 2030, subject to the Reporting Person's continued service with the Issuer on each such vesting date. |
Common Stock
|
45,000 |
| 2026-02-26 | Loomis David K |
VP, Chief Accounting Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted by the Issuer on February 26, 2026, pursuant to the Plan. The shares underlying the option vest over four years: one-quarter of the shares underlying the award will vest on February 26, 2027, with the remainder of the shares vesting in equal monthly installments following February 26, 2027 through February 26, 2030, subject to the reporting person's continued service with the Issuer on each vesting date. |
Stock Option (right to buy)
|
18,504 |
| 2026-02-26 | Cacace Angela M |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted by the Issuer on February 26, 2026, pursuant to the Plan. The shares underlying the option vest over four years: one-quarter of the shares underlying the award will vest on February 26, 2027, with the remainder of the shares vesting in equal monthly installments following February 26, 2027 through February 26, 2030, subject to the reporting person's continued service with the Issuer on each vesting date. |
Stock Option (right to buy)
|
67,000 |
| 2026-02-26 | Loomis David K |
VP, Chief Accounting Officer |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock units (each, an "RSU") were granted by the Issuer on February 26, 2026, pursuant to its 2018 Stock Incentive Plan (the "Plan"), and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: one-quarter of the RSUs will vest on each of February 26, 2027, February 26, 2028, February 26, 2029 and February 26, 2030, subject to the Reporting Person's continued service with the Issuer on each such vesting date. |
Common Stock
|
12,420 |
| 2026-02-26 | Saik Andrew |
Director, Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted by the Issuer on February 26, 2026, pursuant to the Plan. The shares underlying the option vest over four years: one-quarter of the shares underlying the award will vest on February 26, 2027, with the remainder of the shares vesting in equal monthly installments following February 26, 2027 through February 26, 2030, subject to the reporting person's continued service with the Issuer on each vesting date. |
Stock Option (right to buy)
|
67,000 |
| 2026-02-26 | Berkowitz Noah |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock units (each, an "RSU") were granted by the Issuer on February 26, 2026, pursuant to its 2018 Stock Incentive Plan (the "Plan"), and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: one-quarter of the RSUs will vest on each of February 26, 2027, February 26, 2028, February 26, 2029 and February 26, 2030, subject to the Reporting Person's continued service with the Issuer on each such vesting date. |
Common Stock
|
45,000 |
| 2026-02-26 | Berkowitz Noah |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted by the Issuer on February 26, 2026, pursuant to the Plan. The shares underlying the option vest over four years: one-quarter of the shares underlying the award will vest on February 26, 2027, with the remainder of the shares vesting in equal monthly installments following February 26, 2027 through February 26, 2030, subject to the reporting person's continued service with the Issuer on each vesting date. |
Stock Option (right to buy)
|
67,000 |
| 2026-02-26 | Cacace Angela M |
Chief Scientific Officer |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock units (each, an "RSU") were granted by the Issuer on February 26, 2026, pursuant to its 2018 Stock Incentive Plan (the "Plan"), and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: one-quarter of the RSUs will vest on each of February 26, 2027, February 26, 2028, February 26, 2029 and February 26, 2030, subject to the Reporting Person's continued service with the Issuer on each such vesting date. |
Common Stock
|
45,000 |
| 2026-02-23 | Teel Randy |
Director, President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on February 23, 2024. The sale does not represent a discretionary trade. |
Common Stock
|
3,748 |
| 2026-02-23 | Cacace Angela M |
Chief Scientific Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on February 23, 2024. The sale does not represent a discretionary trade. |
Common Stock
|
2,571 |
| 2026-02-23 | Cacace Angela M |
Chief Scientific Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-quarter of the reporting person's restricted stock units (RSUs) granted on February 22, 2023. The sale does not represent a discretionary trade. |
Common Stock
|
1,038 |
| 2026-02-23 | Teel Randy |
Director, President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-quarter of the reporting person's restricted stock units (RSUs) granted on February 22, 2023. The sale does not represent a discretionary trade. |
Common Stock
|
1,038 |
| 2026-02-23 | Loomis David K |
VP, Chief Accounting Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on February 23, 2024. The sale does not represent a discretionary trade. |
Common Stock
|
1,108 |
| 2026-02-13 | Cacace Angela M |
Chief Scientific Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on February 13, 2025. The sale does not represent a discretionary trade. Includes an aggregate of 1,576 shares of common stock of the Issuer previously purchased under and in accordance with the 2018 Employee Stock Purchase Plan of the issuer in transactions exempt under Rule 16b-3. |
Common Stock
|
4,592 |
| 2026-02-13 | Loomis David K |
VP, Chief Accounting Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on February 13, 2025. The sale does not represent a discretionary trade. Includes an aggregate of 119 shares of common stock of the issuer previously purchased under and in accordance with the 2018 Employee Stock Purchase Plan of the issuer in transactions exempt under Rule 16b-3. |
Common Stock
|
1,016 |
| 2026-02-13 | Saik Andrew |
Director, Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on February 13, 2025. The sale does not represent a discretionary trade. |
Common Stock
|
5,134 |
| 2026-02-13 | Berkowitz Noah |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on February 13, 2025. The sale does not represent a discretionary trade. |
Common Stock
|
5,685 |
| 2026-02-13 | Teel Randy |
Director, President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on February 13, 2026. The sale does not represent a discretionary trade. |
Common Stock
|
4,403 |
| 2025-11-07 | Loomis David K |
VP, Chief Accounting Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on December 13, 2022. Includes an aggregate of 1,239 shares of common stock of the issuer previously purchased under and in accordance with the 2018 Employee Stock Purchase Plan of the issuer in transactions exempt under Rule 16b-3. |
Common Stock
|
230 |
| 2025-09-22 | Morrison Briggs |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The purchase price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.50 to $7.65, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
Common Stock
|
30,000 |
| 2025-06-25 | Kennedy Edward Moore Jr. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option award was granted on June 25, 2025. The shares underlying the award shall vest in full on the earlier of June 25, 2026 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders, subject to the reporting person's continued service with the Issuer on the vesting date. |
Stock Option (right to buy)
|
23,105 |
| 2025-06-25 | AGARWAL SUNIL |
EVP, Head of Development & CMO |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock units (each, an "RSU") were granted by the Issuer on June 25, 2025 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of June 25, 2026 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders, subject to the reporting person's continued service with the Issuer on the vesting date. |
Common Stock
|
16,025 |
| 2025-06-25 | Norwalk Leslie V |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock units (each, an "RSU") were granted by the Issuer on June 25, 2025 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of June 25, 2026 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders, subject to the reporting person's continued service with the Issuer on the vesting date. |
Common Stock
|
16,025 |
| 2025-06-25 | AGARWAL SUNIL |
EVP, Head of Development & CMO |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option award was granted on June 25, 2025. The shares underlying the award shall vest in full on the earlier of June 25, 2026 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders, subject to the reporting person's continued service with the Issuer on the vesting date. |
Stock Option (right to buy)
|
23,105 |